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Addition of AT1 blocker fails to overcome resistance to ACE Proteinuria is an important determinant of progressive
inhibition in adriamycin nephrosis. renal damage in human and experimental renal disease
Background. Angiotensin-converting enzyme (ACE) inhib- [1, 2]. Reduction of proteinuria plays a key role in theitors provide renoprotection, but there is considerable inter-
renoprotective effect of intervention therapy [3–5]. Thusindividual variability in therapeutic efficacy, with residual pro-
far, angiotensin-converting enzyme (ACE) inhibitors areteinuria and progressive renal function loss in many individuals.
This requires additional strategies to optimize therapy response, the most effective class of antiproteinuric and renopro-
particularly for individuals with a poor response to ACE inhibi- tective drugs. Nevertheless, the response to ACE inhibi-
tion. We studied whether co-treatment with an angiotensin II tion appears to vary between individuals, with consider-subtype 1 (AT1) receptor antagonist (AII-A) improves the in-
able residual proteinuria and considerable residual glo-dividual antiproteinuric response of maximal ACE inhibition
merular filtration rate (GFR) loss in many patients [6, 7].in established adriamycin nephrosis.
Methods. Rats were instituted on lisinopril (75 mg/L) six As residual proteinuria predicts a poor long-term renal
weeks after disease induction. After two weeks rats were re- prognosis [8], one could monitor the improvement of
stratified for residual proteinuria to continue this regimen,
the therapeutic efficacy using proteinuria as a parameter.to a higher dose of lisinopril (150 mg/L) or to co-treatment
We found that resistance to the antiproteinuric effect ofwith the AII-A L 158,809 for another four weeks. Groups on
monotherapy AII-A and vehicle served as controls (all groups ACE inhibition appears to be an individual characteris-
N  15). tic, that is independent of the underlying renal disorder
Results. Lisinopril lowered proteinuria by 63% from 741 to and cannot be overcome by application of monotherapy
246 g/day (range of percentage change 90 to 2%). Neither
of drugs from other therapeutic classes [9].increasing the dose of the ACE inhibitor nor addition of AII-A
A possible cause of individual therapy resistance couldto ACE inhibition improved the antiproteinuric efficacy on
a group or individual level: non-responders remained non- be the dose of the drug. The optimal antiproteinuric
responders. All drug categories reduced hard end-points of dose of ACE inhibition is established on the basis of
focal glomerulosclerosis to a similar degree. group averages [1]. However, it could well be that someConclusions. ACE inhibition has variable renal protective
individuals benefit from an even higher dose.efficacy in the adriamycin model. Neither increasing the dose
Another possible cause of therapy resistance to ACE-of the ACE inhibitor beyond the optimal level nor co-treat-
ment with AII-A overcome the individual therapy resistance. inhibition could be ongoing formation of angiotensin II
Thus, in established adriamycin nephrosis, blockade of the by non–ACE-pathways or by insufficient ACE blockade
renin-angiotensin system at two different levels offers no addi- [10, 11]. As the pathophysiological effects of angio-tional benefit over ACE inhibition alone, either on the group
tensin II are assumed to be mediated by the angioten-or individual level.
sin II subtype 1 (AT1) receptor [12, 13], co-treatment
with an AT1-receptor antagonist (AII-A) might improve
therapy response in individuals resistant to the effects
of ACE-inhibition.
There is evidence to suggest that the combination of
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ACE inhibition and AII-A displays superior therapeuticnoprotection, lisinopril, angiotensin II subtype 1 receptor, combination
therapy. efficacy to monotherapy ACE inhibition alone in experi-
mental [14, 15] as well as in human [16, 17] renal disease.Received for publication August 21, 2000
However, so far no studies applied the combination asand in revised form September 13, 2001
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In adriamycin nephrosis, a model of proteinuria-induced 2002 by the International Society of Nephrology
473
Bos et al: Therapy resistance is individually determined474
renal damage, the interindividual variability in antipro- induces a modest and stable proteinuria [18]. Six weeks
after disease induction, the rats were stratified for pro-teinuric effect of ACE inhibition closely resembles the
response in proteinuric patients and the individual long- teinuria (mean of weeks 5 and 6). Forty-five rats were
treated with the ACE inhibitor lisinopril (75 mg/L drink-term renoprotective effect of ACE inhibition is consis-
tently predicted by the early antiproteinuric response ing water), 15 rats with the AT1-receptor antagonist
(AII-A) L 158,809 (100 mg/L drinking water) and 15[1]. Thus, animals with a good or poor long-term re-
sponse can be reliably identified early in the course of rats with vehicle. This dose of lisinopril was based on
previous studies in our laboratory showing that this dosetreatment. This enables a study design where individuals
can be randomized according to their early response yielded the maximum antiproteinuric effect [1]. The dose
of AII-A was based on previous studies in the adriamycinto ACE inhibition to investigate the subsequent added
effect of AII-A or higher dose of ACE inhibition. model [19].
After two weeks of treatment, the lisinopril groupIn this model we therefore studied the efficacy of com-
bined treatment of ACE inhibition with AII-A and dou- was re-stratified in three groups (each N  15, Fig. 1)
according to residual proteinuria in week 8. In the firstbling the dose of the ACE inhibitor, respectively, as
a means to overcome individual therapy resistance to group, AII-A (L 158,809; 100 mg/L) was added to the
lisinopril. In the second group the dose of lisinopril wasmonotherapy ACE inhibition, as established from the
response to initial treatment with ACE inhibition. doubled to 150 mg/L to verify that 75 mg/L was on
the top of the dose response curve. The third group
continued on lisinopril 75 mg/L. Treatment was contin-
METHODS
ued for another four weeks.
The protocol was approved by the Committee for Ani- In week 12, that is, six weeks after start of treatment,
mal Experiments of the University of Groningen, The rats were sacrificed under anesthesia with isoflurane/
Netherlands. Adult male Wistar rats (N  75; Hsd.Cpd. N2O/O2 and blood was collected by puncture of the ab-
Wu; Harlan Inc., Zeist, The Netherlands) were studied. dominal aorta. Kidneys were perfused with saline and
Throughout the experiment the rats were housed in a harvested for histological examination and determina-
temperature-controlled room with a 12-hour light–dark tion of renal ACE activity. Tissue processing was per-
cycle. All animals were fed a low sodium diet (0.05% formed as described earlier by Van Goor et al [20]. ACE
sodium, 20% protein; Hope Farms Inc., Woerden, The activity was measured as the rate of cleavage of Hip-
Netherlands) ad libitum and received daily fresh tap His-Leu, as reported previously [21, 22].
water ad libitum.
Histological examination
Measurements During histological examination the degree of focal
Body weight, food and water intake, proteinuria and segmental glomerulosclerosis was scored semiquantita-
systolic blood pressure were measured once a week dur- tively in a blinded, randomized manner. Focal segmental
ing the entire protocol. Food and water intake and pro- glomerulosclerosis was scored positive when mesangial
teinuria were measured in individual rats during a 24-hour expansion, mesangial cellularity, adhesion formation and
stay in metabolic cages with free access to food and water. capillary obliteration were present in one segment. If 25%
This allowed a calculation of individual differences in of the glomerulus was affected a score of 1 was given,
drug intake as possible confounders. Blood pressure was 50% was scored as 2, 75% as 3, and 100% as 4. In both
measured as systolic blood pressure in conscious rats kidneys of each animal 100 randomly chosen glomeruli
with an automated multichannel system using tail cuffs were examined. Their scores were added and the mean
and photoelectric sensors (Apollo 179; IITC Life Sci- of the scores of both kidneys is given [23].
ence, Woodland Hills, CA, USA). The rats were placed Interstitial injury was scored semiquantitatively on a
in the test chamber in restrainers at 28 to 29C. During scale of 0 to 3, regarding tubular dilation and/or atrophy,
each measurement session, three measurements were interstitial fibrosis, and inflammatory cell infiltrates. The
recorded for each animal. The value for blood pressure mean of the scores of both kidneys is given.
was taken as the mean of these three recordings. Animals
Data analysiswere trained for two weeks before study entry to become
accustomed to handling, metabolic cages and blood pres- Data are expressed as median and 95% confidence
sure measurements. interval (CI). Baseline values are the mean of the values
in weeks 5 and 6. The 95% CI was calculated according to
Protocol the Binomial distribution with probability 1⁄2 [24]. Ranges
To induce proteinuria, the rats were anesthesized with are given when appropriate.
isoflurane/N2O/O2 and 1.5 mg/kg adriamycin was injected Statistical analysis was performed by one-way ANOVA
with a post-test according to Bonferroni in case of para-in the penis vein. In our hands, this dose of adriamycin
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Fig. 1. Scheme of the study. Induction of ne-
phrosis at week 0. Stratification at week 6 ac-
cording to baseline proteinuria. Forty-five rats
were treated by lisinopril 75 mg/L during two
weeks. These rats were re-stratified at week
8 according to residual proteinuria. AII-A is
angiotensin II inhibitor.
Table 1. Pre-treatment parameters (median, 95% CI)metric distribution of data and by ANOVA on ranks
with a posttest according to Dunn’s method in case of Blood pressure Proteinuria
mm Hg mg/daynon-parametric distribution of data with the vehicle
Vehicle 140 (136–147) 760 (468–971)treated group as control group. Differences between pre-
Lisinopril 75 mg/L 146 (128–150) 780 (477–892)and post-treatment values of the same group were com-
Lisinopril 150 mg/L 144 (132–150) 678 (460–1024)
pared by paired t test. Correlations were determined by AII-A 139 (131–152) 695 (451–946)
LisinoprilAII-A 144 (137–156) 735 (388–1026)the Pearson method. Statistical significance was assumed
at the 5% level. Statistical analysis was performed using No statistical significant changes were found between groups.
SPSS 8.0 (SPSS, Inc., Chicago, IL, USA).
The design with re-stratification for response to mo-
notherapy ACE inhibition permitted an analysis for the
(range 35 to 31%). Monotherapy lisinopril 75 mg/Lrole of individual responsiveness to monotherapy ACE
reduced proteinuria by 63 (range of percentage changeinhibition in the response to co-treatment with AII-A.
90 to 2) % during the first two weeks of treatment,To this purpose, first, the added value of co-treatment
resulting in a proteinuria of 246 (range 18 to 1119) mg/was assessed for individual rats (N  15) by comparing
day at week 8. In the animals that continued on lisinoprilthe individual response to monotherapy lisinopril (week 8)
75 mg/L, proteinuria was reduced by 85% (range ofwith the response to co-treatment with AII-A (week 12).
percentage change 96 to 17) at week 12. As in ourSecond, the responses at week 12 to the different treat-
earlier studies [1, 18], residual proteinuria of this groupment regimens were compared according to a break-up
at week 8 correlated positively with proteinuria at week 12for good versus poor response (defined as an antiprotein-
(r  0.74, P  0.01). Thus, the antiproteinuric responseuric response better or worse than the group median)
at week 8 predicts the response at week 12, indicatingto monotherapy ACE inhibition at week 8. Finally, we
that poor or good responders can be reliably identifiedalso compared the group outcomes at week 12 for the
at week 8. Water intake, and thus lisinopril intake, wasdifferent parallel treatment groups.
similar in poor (40 mL/rat/day; range 32 to 44) and good
(38 mL/rat/day; 32 to 42) responders at week 8.
RESULTS On a group basis, the antiproteinuric efficacy of co-
treatment of lisinopril with AII-A at week 12 was com-Six weeks after the injection of adriamycin proteinuria
parable to monotherapy lisinopril (Table 2). Individualwas stabilized at 741 (range 125 to 1101) mg/day (N 
responses to monotherapy ACE inhibition and the sub-75). After stratification baseline data were comparable
sequent efficacy of co-treatment with AII-A are shownin all groups (Table 1). In the vehicle group proteinuria
in Figure 2, which illustrates a strong positive correlationremained stable during the following six weeks (Table 2;
(r 0.87, P 0.01). The responses are scattered aroundpaired t test, P  0.88). The median percentage change
of proteinuria between week 6 and week 12 was 0% the line of identity, without an apparent specific benefit
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Table 2. Post-treatment parameters (median, 95% CI)
Change of proteinuria Focal
Blood pressure Proteinuria from baseline glomerulosclerosis Interstitial injury
mm Hg mg/day % (0–400) (0–3)
Vehicle 137 (113–149) 672 (523–1001) 0 (18–26) 61 (14–98) 0.50 (0.0–1.0)
Lisinopril 75 mg/L 88 (67–113)a 113 (52–311)a 85 (91–62)a 20 (10–67) 0.00 (0.0–1.5)
Lisinopril 150 mg/L 80 (58–113)a 62 (21–289)a 87 (96–70)a 19 (10–54) 0.00 (0.0–1.0)
AII-A 105 (82–133)a 170 (62–691)a 74 (85–44)a 20 (10–78) 0.00 (0.0–1.5)
LisinoprilAII-A 92 (74–115)a 218 (61–789)a 64 (84–16)a 16 (7–153) 0.25 (0.0–2.0)
a P  0.05 versus vehicle treated animals.
six weeks onwards proteinuria fell significantly, demon-
strating the antiproteinuric efficacy of AII-A (Table 2).
Systolic blood pressure was normal in the vehicle
treated rats. Systolic blood pressure was reduced by all
active treatment regimens (Table 2). Blood pressure was
lower with lisinopril than with the other regimens, but
this difference did not reach statistical significance. No
differences in systolic blood pressure were present be-
tween good and poor responders in the pre-treatment
and post-treatment period in the lisinopril 75 mg/L group
and in the co-treatment group. Moreover, the percentage
of changes in blood pressure also was not different in
these groups. In the lisinopril 150 mg/L group blood pres-
sure response was less pronounced in the poor respond-
ers, resulting in a higher post-treatment systolic blood
pressure and a lower percentage change (both P 0.01).
The percentage changes of blood pressure and of pro-
teinuria correlated in both the lisinopril 75 mg/L (r 
0.67, P  0.05) and the lisinopril 150 mg/L group (r 
Fig. 2. Correlation of the antiproteinuric response to initial treatment 0.64, P  0.05), but not in both other active treat-
with monotherapy lisinopril at week 8 and to subsequent co-treatment ment groups.
with angiotensin II subtype 1 receptor antagonist (AII-A) at week 12.
Body weight was comparable in all groups at the endThe line of identity is shown.
of the study, but the rats in the lisinopril 150 mg/L group
gained significantly less body weight during the treat-
ment period compared to the vehicle group, despite a
of co-treatment in rats with a poor response to mono- comparable food intake (Table 3).
therapy ACE inhibition. When analyzed according to a Focal segmental glomerulosclerosis scores as well as
break-up for good versus poor response (Fig. 3), no spe- interstitial injury scores were comparable in all active
cific benefit in poor responders was found either. treatment groups (Table 2). Focal glomerulosclerosis
To test whether individual responses could be im- scores correlated with proteinuria at the end of the study
proved by a higher dose, the dose of lisinopril was dou- in the vehicle group (r  0.75, P  0.01) as well as in all
bled to 150 mg/L for four weeks in 15 rats, after re- active treatment groups (Fig. 4). Interstitial injury score
stratification at week 8. Antiproteinuric efficacy in the correlated positive with proteinuria at the end of the study
lisinopril 150 mg/L group was comparable to the lisino- as well as with focal glomerulosclerosis score (Fig. 4).
pril 75 mg/L group at week 12 (Table 2 and Fig. 3). There To check the efficacy of ACE blockade, plasma and
was a strong positive correlation (r  0.81, P  0.001) renal ACE activity was determined. Lisinopril signifi-
between the antiproteinuric response to 75 mg/L lisino- cantly reduced both plasma and renal ACE activity at
pril at week 8 and to 150 mg/L lisinopril at week 12. week 12 (Table 4). No further reduction in plasma and
Again, improvement of therapeutic efficacy of lisinopril renal ACE activity was achieved by doubling the dose of
150 mg/L versus 75 mg/L was not only absent in the lisinopril. Co-treatment of lisinopril and AII-A reduced
whole group at week 12, but also in the good and poor plasma and renal ACE activity as well, while mono-
responders separately (Fig. 3). therapy AII-A did not affect ACE activity. During chronic
ACE inhibition, including the combined treatment group,In the group treated with monotherapy Ang IIA from
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Fig. 3. Proteinuria (median and 95% CI) at onset of treatment (week 6; stratification), after two weeks of monotherapy lisinopril (week 8, re-
stratification) and at week 12 (end of study) according to final treatment regimen. Data are given for the whole group, and according to a break-up
for good and poor response to the initial two weeks of angiotensin-converting enzyme (ACE) inhibition.
Table 3. Group characteristics at the end of the study To focus on individual responsiveness, we chose a study
(median, 95% CI)
design that enables early identification of therapeutic
Body weight Food intake Water intake response to monotherapy ACE inhibition in individual
g g/day mL/day
animals, thus ensuring an equal distribution of response
Vehicle 436 (368–478) 17 (12–20) 31 (21–36) amongst study groups. In this set-up, rats were re-strati-
Lisinopril 75 mg/L 398 (357–425) 21 (14–23) 44 (37–50)a
fied according to their initial response to two weeks ofLisinopril 150 mg/L 390 (351–409)a 20 (14–25) 42 (32–60)a
AII-A 435 (407–452) 18 (14–22) 30 (18–51) monotherapy lisinopril, as the response at this time was
LisinoprilAII-A 412 (364–436) 19 (13–22) 30 (22–38) found highly indicative for the final therapeutic efficacy
a P  0.05 versus vehicle treated animals. [1]. In agreement, the present study found a good corre-
lation between the antiproteinuric response at week 2
and the final antiproteinuric response at week 6 in the
no correlation was present between individual water (li- group treated with monotherapy lisinopril 75 mg/L. A sec-
sinopril) intake and renal ACE activity. Moreover, also ond crucial aspect of the study design was to establish
at week 12 water intake was similar in the poor (37 mL/ maximal efficacy of lisinopril in all rats. The dose of
rat/day; range 31 to 43) and good (41 mL/rat/day; 31 75 mg/L lisinopril was based on previous studies in our
to 45) responders. No correlation was present between laboratory, showing that this dose is on the top of the
individual water intake and antiproteinuric response. dose-response. As the dose-response was determined as
the mean response of a group of rats, however, it is
conceivable that individual rats would require a higherDISCUSSION
dose for optimal ACE inhibition. Therefore, the presentIn this study in established adriamycin nephrosis mo-
study tested the double dose as well. Both the data onnotherapy, as anticipated, lisinopril reduced proteinuria
therapy response, notably the absence of an added effectwith large individual differences. Neither doubling of the
of the double dose in poor responders, and on plasmadose nor co-treatment with AII-A could improve a poor
and tissue ACE activity suggest that optimal pharmaco-individual response to lisinopril. Control experiments
logical efficacy of the ACE inhibitor was obtained in-confirmed the antiproteinuric efficacy of monotherapy
deed. Finally, an adequate dose of AII-A was used, asAII-A. These data suggest that a poor individual re-
shown by the therapeutic efficacy of monotherapy AII-A.sponse to ACE inhibition in this model is not likely to
be due to ongoing effects of angiotensin II. Together, these results confirm the validity of the study
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Fig. 4. Correlation between residual protein-
uria at week 12, that is, at the end of the study,
and the focal glomerulosclerosis score (FGS
score, left Y-axes,) as well as the interstitial
injury score (right Y-axes, ) in all groups on
active treatment. For clarity, only the regres-
sion line and correlation coefficient of the
correlation between residual proteinuria and
FGS score are shown.
Table 4. ACE activity at the end of the study (median, 95% CI) When evaluated on group level, antiproteinuric effi-
cacy of ACE inhibition was not improved by additionKidney Plasma
nmol/g/min nmol/mL/min of AII-A either. Several experimental and clinical studies
Vehicle 271 (136–306) 56 (38–61) have assessed the therapeutic benefit of combined AII-A
Lisinopril 75 mg/L 27 (10–58)a 7 (3–9)a and ACE inhibition, as compared to monotherapy ACE
Lisinopril 150 mg/L 16 (8–28)a 3 (1–8)a
inhibition. Whereas a number of studies reached a simi-AII-A 177 (118–406) 83 (74–92)
LisinoprilAII-A 48 (28–85)a 17 (7–27)a lar conclusion our current results [25–28], other studies
described an additional effect of AII-A on ACE inhib-a P  0.05 versus vehicle treated animals.
itor treatment [14–17, 29]. Most likely, this discrepancy
can be explained by suboptimal dosing of the ACE inhib-
itor in the studies that found an additional effect of
design to enable testing of the additional effect of AII-A AII-A. In rat studies, suboptimal dosing of ACE inhibi-
on monotherapy lisinopril. tion seems conceivable as the animal models used—SHR
Reduction of proteinuria is the main surrogate param- and (mREN-2)27 rats—display increased activity of the
eter for long-term protection against progressive renal renin-angiotensin system (RAS). In the human studies,
damage [3–5]. This was also true in our study, as demon- ACE inhibition was either not used at maximal dose [15]
strated by the strong correlation between residual pro- or the data were not supplied [16, 17]. Alternatively,
teinuria and focal glomerulosclerosis, irrespectively of non-ACE conversion of angiotensin I to angiotensin II
the mode of treatment. Results on interstitial damage may be responsible for the observed efficacy of co-treat-
were in line with results on focal glomerulosclerosis. ment with AII-A. This would apply principally to the
Thus, the failure of the co-treatment regimen and the clinical studies, as in humans several non-ACE pathways
double dose regimen to improve individual antiprotein- are operational, especially the chymase pathway, while
uric efficacy also is associated with a poor outcome as their contribution in rodents seems limited [30]. For the
rat model and the lisinopril regimen used in the presentto renal structural damage.
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study, however, we recently demonstrated that the effects with ACE inhibition and mycophenolate mofetil [34], or
ACE inhibition and lipid-lowering drugs [35]. Finally,of ACE-inhibition are specific for RAS blockade [19].
Our current study design has the advantage permitting the clinical advantage of using a combination of ACE in-
hibition and AII-A, both at lower dose (to obtain a similaran assessment of the individual effects of co-treatment
in animals characterized for their response to ACE inhi- effect with a high dose of either one), could still be present
bition. In humans, we recently found that the respon- because of fewer clinical side effects.
siveness to antiproteinuric therapy is individually deter-
mined as (1) the individual differences to antiproteinuric ACKNOWLEDGMENTS
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